登录 查看组织和合同定价。
选择规格
变更视图
关于此项目
经验公式(希尔记法):
C22H23ClN2O2
化学文摘社编号:
分子量:
382.88
UNSPSC Code:
12352200
MDL number:
NACRES:
NA.21
Assay:
≥98% (HPLC)
Form:
powder
Quality Segment
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 2 mg/mL, clear
storage temp.
-10 to -25°C
SMILES string
ClC1=CC=C(C(NCC2=CC=C(C)C(O)=C2)=C1)NCC3=CC=C(C)C(O)=C3
InChI
1S/C22H23ClN2O2/c1-14-3-5-16(9-21(14)26)12-24-19-8-7-18(23)11-20(19)25-13-17-6-4-15(2)22(27)10-17/h3-11,24-27H,12-13H2,1-2H3
InChI key
WNTAQMQIZGJASL-UHFFFAOYSA-N
Biochem/physiol Actions
Class I glucose transporters (GLUT1-4) inhibitor with greater anti-cancer efficacy than WZB117 (WZB-117) in cultures and in vivo.
DRB18 is a class I glucose transporters (GLUT1-4) inhibitor (glucose uptake IC50 = 2.6/8.8/4.5/0.9 µM using HEK293 GLUT1/2/3/4 transfectants) that exhibits greater anti-cancer efficacy than WZB117 (WZB-117) in cultures (IC50 <10 µM in 51 of 60 cancer cultures tested vs. only 17 from the same 60 cultures when using WZB117) and suppresses A549 xenografts-derived tumor growth in mice in vivo (44% reduction with 10 mg/kg i.p. 3x per wk for 5 wks) by altering the abundance of metabolites in glucose-related pathways.
DRB18 is a class I glucose transporters (GLUT1-4) inhibitor (glucose uptake IC50 = 2.6/8.8/4.5/0.9 µM using HEK293 GLUT1/2/3/4 transfectants) that exhibits greater anti-cancer efficacy than WZB117 (WZB-117) in cultures (IC50 <10 µM in 51 of 60 cancer cultures tested vs. only 17 from the same 60 cultures when using WZB117) and suppresses A549 xenografts-derived tumor growth in mice in vivo (44% reduction with 10 mg/kg i.p. 3x per wk for 5 wks) by altering the abundance of metabolites in glucose-related pathways.
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable